Generate Biomedicines, Inc. (GENB)

Price$16.39Cached quoteAs of 2026-09-05 15:26 UTC

AI: Fair-priced

Price checkTraditional earnings multiples do not work here; valuation mainly reflects pipeline success expectations.

Generate Biomedicines, Inc., traded as GENB on the Nasdaq Global Select Market, is not profitable, so a price-to-earnings ratio is not meaningful. Market data place equity value near $2.0 billion and enterprise value near $1.6 billion after net cash; enterprise value is roughly the market value of the operating business after subtracting cash. Analysts’ average target is materially above the market, a bullish signal, but the current valuation already assigns substantial value to GB-0895 before Phase 3 efficacy results. That supports a fair-priced view rather than an obviously cheap one.

Big pictureA strong cash cushion funds development, but losses and trial spending remain structurally high.

Second-quarter collaboration revenue was $6.3 million and net loss was $67.3 million, while operating cash use reached $138.3 million for the first half. Research spending increased as the global GB-0895 Phase 3 program expanded. Collaboration revenue from Novartis and Amgen is nearing completion of current performance obligations, so it is not durable product revenue. Management expects liquid resources to fund the current plan into the first half of 2028, roughly when full Phase 3 enrollment had been expected.

Business strengthNet cash, partnerships, and a differentiated lead asset offset pre-revenue concentration and funding risk.

At June 30, Generate held $457.4 million of cash, cash equivalents, and marketable securities against modest lease liabilities and no conventional bank or bond debt shown on the balance sheet. Liquidity is therefore strong today. However, first-half stock-based compensation was $14.6 million, and the IPO added 25 million new common shares. Dilution means each existing share represents a smaller ownership percentage. The company says additional long-term capital will be needed. Biotechnology demand is not very economic-cycle sensitive, but financing conditions and clinical catalysts can make the shares highly cyclical and volatile.

What could change the storyPhase 3 efficacy, COPD expansion, partnership economics, and financing terms will dominate future value.

The bull case is that twice-yearly GB-0895 meaningfully reduces severe-asthma exacerbations with clean safety, COPD biomarker effects translate into clinical benefit, and collaborations deliver useful milestones or licensing economics. The bear case is weaker Phase 3 efficacy, slower enrollment, COPD activity remaining biomarker-only, or cash burn staying near current levels. Because the stated runway reaches only into the first half of 2028, another equity raise could dilute holders. Success from GB-4362, GB-5267, or new partners would reduce dependence on one lead asset.

AI: News

COPD data support durabilityERS data showed sustained biomarker suppression after one GB-0895 dose, supporting six-month dosing in COPD.

On September 8, Generate posted final Phase 1 COPD data from 40 participants. GB-0895 showed an approximately 98-day half-life and reductions in eosinophils, FeNO, IL-5, and IL-13 sustained for at least six months; the 300 mg dose produced pharmacodynamic suppression comparable with 600 mg. In blinded pooled safety data, most treatment-emergent adverse events were mild or moderate, with no treatment-related serious events. The evidence is encouraging mechanistically, but the small study was not designed to prove clinical outcomes such as fewer exacerbations.

Phase 3 rollout advancesGlobal asthma studies expanded across six regions while newer oncology programs moved further into clinical development.

On August 6, Generate said SOLAIRIA-1 and SOLAIRIA-2 had regulatory approvals in 33 countries within a planned 42-country program, with recruitment underway across all six global regions. The first GB-4362 cohort was fully enrolled and initial patients had been dosed, while GB-5267 was recruiting. Novartis also advanced a platform-designed biologic into its preclinical pipeline. The update showed broad execution, although the expanding pipeline is increasing research spending and cash consumption.

Draft posters surfaced earlyAn embargo mishap exposed three ERS posters early, underscoring catalyst sensitivity around GB-0895 clinical disclosures.

On August 25, Generate filed an 8-K after draft copies of three ERS posters were inadvertently made public before the expected embargo expired. The posters covered asthma Phase 1 durability, the SOLAIRIA Phase 3 designs, and COPD Phase 1 data. The filing did not announce a financing, regulatory decision, or completed efficacy endpoint, but it highlighted how incremental clinical information can quickly influence expectations for a pre-commercial biotechnology company whose valuation depends heavily on one lead program.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2024

2025

Financial statements

	2025	2024
Revenue	$31.9M	$20.5M
Research & development	$175.3M	$1,000
Operating expenses	$267.0M	$217.4M
Operating income	−$235.1M	−$196.9M
Operating margin	−737.04%	−962.60%
EBITDA	−$221.9M	−$181.6M
EBITDA margin	−695.72%	−887.58%
Net income	−$223.0M	−$181.4M
Net profit margin	−699.10%	−886.57%
Basic EPSper basic share	-$2.18	-$2.09
Diluted EPSper diluted share	-$11.50	-$10.12

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

≈48.86%of listed shares

Flagship Pioneering Fund VI, L.P. / FPN II, L.P. / Flagship VentureLabs VI LLC / Nutritional Health LTP Fund, L.P. / Flagship Pioneering Special Opportunities Fund II, L.P. / AFEYAN NOUBAR / Flagship Pioneering Fund VII, L.P.62.67M shares · Mar 2, 2026

View holders

Top 20 reported holders of GENB
Holder	% owned
Flagship Pioneering Fund VI, L.P. / FPN II, L.P. / Flagship VentureLabs VI LLC / Nutritional Health LTP Fund, L.P. / Flagship Pioneering Special Opportunities Fund II, L.P. / AFEYAN NOUBAR / Flagship Pioneering Fund VII, L.P.	≈48.86%62.67M shares
Flagship Pioneering, LLC	48.86%62.67M shares
FMR LLC	4.07%5.22M shares
Capital World Investors	3.29%4.22M shares
BRAIDWELL LP	2.56%3.28M shares
Nally Michael	≈2.25%2.89M shares
PRICE T ROWE ASSOCIATES INC /MD/	1.68%2.16M shares
NORGES BANK	1.63%2.09M shares
ARCH Venture Management, LLC	1.52%1.94M shares
HarbourVest Partners LLC	1.34%1.72M shares
BlackRock, Inc.	1.29%1.66M shares
Pioneering Medicines 02, LLC	≈1.22%1.56M shares
BAKER BROS. ADVISORS LP	1.11%1.42M shares
JPMORGAN CHASE & CO	1.10%1.41M shares
Deep Track Capital, LP	1.04%1.33M shares
ARK Investment Management LLC	1.00%1.28M shares
Bancel Stephane	≈0.92%1.18M shares
VANGUARD CAPITAL MANAGEMENT LLC	0.88%1.13M shares
HARVARD MANAGEMENT CO INC	0.87%1.11M shares
NVIDIA CORP	0.65%833.33K shares

Percentages use 128.27M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Reported positions exceed 100% in total, so the circle shows the selected holder only.

Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys12$150.30M disclosed value

Sells (SEC code S)0$0.00 disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Mar 4, 2026Form 4	Nally MichaelChief Executive Officer	BuyCommon Stock	20.0K	$12.00	$240.0K	572.7K
Mar 2, 2026Form 4	Grous BethChief People Officer	BuyCommon Stock · indirect	300	$16.00	$4.8K	300
Mar 2, 2026Form 4	Silvers JasonPresident & CFO	BuyCommon Stock · indirect	1.0K	$16.00	$16.0K	1.0K
Mar 2, 2026Form 4	Silvers JasonPresident & CFO	BuyCommon Stock · indirect	500	$16.00	$8.0K	500
Mar 2, 2026Form 4	Silvers JasonPresident & CFO	BuyCommon Stock · indirect	500	$16.00	$8.0K	500

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about GENB yet. Start the conversation.

Write the first post

Generate Biomedicines, Inc. (GENB)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.